Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Ipsen

Clinicaltrial registered18 Nov 2026

Ipsen

18 Nov 2026: Trial registered · A Phase I/II Study to Learn About the Safety and Effects of a New Medicine Called IPN60350 Alone or in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Solid Tumors. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
18 Nov 2026
Title
A Phase I/II Study to Learn About the Safety and Effects of a New Medicine Called IPN60350 Alone or in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Solid Tumors
Conditions
Neoplasms, Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes
Phase
Phase 1, Phase 2
Study Type
Interventional
Status
Not Yet Recruiting
Reference
NCT07944144
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Ipsen

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

Across AOS Research

Other records for Ipsen in our registers.

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.